tbuckley/cabot-search huggingface dataset:
Risk of fatigue with the targeted therapy for renal cell carcinoma.
Authors: Bilal Iqbal, Shenhong Wu
Journal: Journal of Clinical Oncology (2013)

e20611 Background: Fatigue is one of the major side effects associated with targeted therapeutic agents in the treatment of renal cell carcinoma (RCC), and has negatively affected the optimal use of these drugs. Currently the risk of fatigue has not been well defined. We performed a systematic review and meta-analysis of published randomized controlled clinical trials (RCT) to determine the risk of fatigue in RCC patients treated with targeted therapy. Methods: Databases including PUBMED, Web of Science, and abstracts presented at the American Society of Clinical Oncology meetings up to October, 2012 were searched to identify relevant studies. Eligible studies included prospective RCTs in which a targeted therapy was compared to a control of non-targeted therapy (placebo or interferon) with data available. Incidences and relative risk (RR) were calculated using a random- or fixed-effects model depending on the heterogeneity of the included studies. Results: A total of 5,192 RCC patients (targeted therapy: 3023, control: 2092) from 11 RCTs were selected for analysis. The overall incidences of all-grade and high-grade (ie, grade 3 or above) fatigue were 45.4% (95% CI: 33.0-58.5%) and 7.6% (95% CI: 4.1-13.5%) respectively. The incidences varied significantly among different agents (P&lt;0.001). In comparison with overall controls, the targeted therapy did not significantly increase the risk of all-grade (RR=1.07, 95% CI: 1.0-1.35, p=0.055) or high-grade fatigue (RR= 1.01, 95% CI: 0.68-1.50, P=0.95). However, the targeted therapy significantly increased the risk of all-grade fatigue (RR 1.60, 95% CI: 1.40-2.32; P&lt;0.001), but not high-grade fatigue (RR 1.74, 95% CI: 0.91-3.32; P=0.095) when compared to placebo. There was no significant difference between the targeted therapy and interferon in the risk of all-grade (RR 1.02, 95% CI: 0.90-1.14; P=0.90) or high-grade fatigue (RR 0.86, 95% CI: 0.55-1.36; P=0.53). Conclusions: The targeted therapy may significantly increase the risk of fatigue in a magnitude comparable to interferon.
CLO20-037: Time is On Our Side: Concomitant Needle Biopsy and Wire-Free Localization of Axillary Lymph Nodes May Decrease Redundant Preoperative Needle Localization in BI-RADS 5, 6 Breast Cancer Patients
Authors: Mary K. Hayes, Mayra Frau, Erica Bloomquist, Heather Wright
Journal: Journal of the National Comprehensive Cancer Network (2020)

"CLO20-037: Time is On Our Side: Concomitant Needle Biopsy and Wire-Free Localization of Axillary Lymph Nodes May Decrease Redundant Preoperative Needle Localization in BI-RADS 5, 6 Breast Cancer Patients" published on 20 Mar 2020 by National Comprehensive Cancer Network.
SURGICAL MANAGEMENT OF MASSIVE AND HIGH-RISK SUBMASSIVE PULMONARY EMBOLISMS RESULTS IN RIGHT VENTRICULAR RECOVERY WITH LOW MORTALITY: INSIGHTS FROM THE LARGEST CASE SERIES
Authors: Joshua Goldberg, Daniel Spevack, Syed A. Ahsan, Yogita M. Rochlani, Tanya Dutta, Suguru Ohira, Masashi Kai, David Spielvogel, Steven Lansman, Ramin Malekan
Journal: Journal of the American College of Cardiology (2020)
Fertility preservation: Utilizing QOPI metrics in the quality improvement efforts of the NCI Community Cancer Centers Program (NCCCP).
Authors: Robert D. Siegel, Donna M. Bryant, Holley Stallings, Pamela Kadlubek, Laurel Borowski, Kathleen M. Castro, Steven B. Clauser
Journal: Journal of Clinical Oncology (2012)

e16532 Background: The NCCCP is a consortium of 30 community based institutions funded by the NCI. Quality of care has been a priority of the NCCCP with participation in the Quality Oncology Practice Initiative (QOPI) serving as a fundamental element in those efforts. QOPI provides both a metric for baseline assessment and a means for measuring improvement across the network. Participation in QOPI became required with expansion of the NCCCP in 2010. Utilizing QOPI methodology, we describe our efforts to optimize adherence to fertility preservation standards of care. NCI Contract No. HHSN261200800001E Methods: A data sharing agreement allows individual practice performance to be electronically forwarded to the NCI twice a year where it is aggregated with the other NCCCP QOPI participants. This allows for ongoing evaluation of group statistics as well as comparisons between participating institutions. Those practices scoring highest on individual parameters are queried for best practices. Results: In Spring 2011, 38 practices/23 NCCCP sites participated resulting in 2653 chart reviews. 258 charts were applicable to fertile individuals as defined by QOPI. 46 charts were in compliance with suggested standards (17.8%) compared with the national rate of 26.1%. Four practices performed well above the national average and became the NCCCP's leaders for establishing best practices. The NCCCP then embarked upon a process of defining barriers to compliance with the fertility preservation recommendations, created an assessment tool by which each practice could identify the degree it integrated fertility preservation into their care models, and began the process of integrating nationally available educational materials and speakers. QOPI metrics will be used to measure the impact of these interventions. Conclusions: QOPI is a useful tool for measuring quality within a network, identifying barriers to compliance with ASCO fertility preservation recommendations and assessing quality improvement efforts. This methodology has allowed us to proceed with quality initiatives despite the logistical challenges of working with institutions and physicians from Maine to Hawaii.
The role of families in decisions about cancer treatments.
Authors: Gabriela Soriano, Mary Beth Landrum, Jane C. Weeks, Neeraj K Arora, Jennifer Malin, Patricia A. Ganz, Michelle van Ryn, Nancy Lynn Keating
Journal: Journal of Clinical Oncology (2013)

6528 Background: Shared decision-making is an important component of patient-centered care and is associated with improved health outcomes. Little is known about patients’ involvement of family members in decisions about cancer treatments or whether family involvement varies by patient demographic or clinical characteristics. Methods: Data for this study were collected as part of the Cancer Care Outcomes Research and Surveillance (CanCORS) study, a large multi-regional prospective cohort study of cancer care and outcomes of lung and colorectal cancer patients. Patients were surveyed about the roles of their families in decisions about surgery, radiation, and/or chemotherapy. We used multinomial logistic regression to identify patient factors independently associated with family roles in decisions. Results: Among 5284 patients, 28.5% reported little or no family input in decisions, 22.1% reported making decisions after considering the family’s opinion, 47.9% reported the patient and family made decisions together, and 1.5% reported the family made decisions. In adjusted analyses, married, female, older, and insured patients were more likely to report making decisions with their family (all P&lt;.001). Family involvement varied substantially by race/ethnicity and language, with Chinese-speaking Asian (63.5%) and Spanish-speaking Hispanic (56.8%) patients reporting making decisions with their family more often than English-speaking Hispanic patients (48.5%) and whites (48.3%). Patients from Veterans Affairs hospitals were least likely to report making decisions together with family (P&lt;.001). Family involvement varied statistically by cancer type, stage, comorbidity, health status, and depression, but differences were minimal. Conclusions: Most patients with a new diagnosis of lung or colorectal cancer involve family members in treatment decisions. Certain groups, such as non-English speaking Hispanics and Asians rely significantly on family; for these groups, it is important that physicians inquire about patients’ preferences for family involvement and work to integrate family members in decisions accordingly. Further studies are needed to determine the impact of family involvement in treatment decisions on oncology outcomes.
Performance of next-generation sequencing for detection of clinically actionable genetic variants in cancer.
Authors: Mohammed Omar Hussaini, Ian S. Hagemann, Teresa Mary Cox, Christina Lockwood, Karen Seibert, Shashikant Kulkarni, John Pfeifer, Eric James Duncavage
Journal: Journal of Clinical Oncology (2013)

11099 Background: Next-generation sequencing (NGS) allows for simultaneous detection of numerous actionable somatic variants in cancer. We have implemented a clinical NGS panel to detect genetic alterations in 25 genes with established roles in cancer and report here the frequency of clinically actionable genetic variants in a variety of cancer types. Methods: NGS testing was performed in a CAP-certified, CLIA-licensed environment on DNA extracted from FFPE tissue in 209 cases spanning 41 histologic tumor types. DNA was enriched by hybrid capture and sequenced to &gt;1,000x average coverage on Illumina sequencers with 2x101bp or 2x150bp reads. Variants were called using clinically validated parameters using the Genome Analysis Toolkit, Pindel, and the custom-written Clinical Genomicist Workstation. Results: Non-small cell lung cancer (45%), pancreatic cancer (10%), and colorectal cancer (8%) were the most common tumors sent for NGS analysis. An average of 3 (range 1- 16) non-synonymous, non-SNP sequence variants per case (SNVs and indels) were detected in the 130kb exonic target. Variants were most commonly seen in TP53, KRAS, and EGFR. 27% of cases (56/209) had one or more variants with therapeutic implications for the tumor type tested (e.g., EGFR mutation in NSCLC). 15% of cases (32/209) showed actionable variants not generally associated with the malignancy tested (e.g., detection of an activating KITvariant in thymic carcinoma). 10% of cases (21/209) had variants that were prognostically significant but not directly targetable. Some cases (9%) had variants that were prognostic/diagnostic and targetable. In 117 cases (56% of total), no therapeutically or prognostically significant variants were identified. Overall, in 92 cases (44%), NGS testing yielded information with therapeutic (majority), prognostic, or diagnostic ramifications. Conclusions: We found that 44% of unselected cancer cases have clinically relevant sequence variants in a set of 25 commonly mutated cancer genes. Our data suggest that clinical NGS testing may serve as an integral tool in realizing the potential of precision medicine in oncology.
Concurrent chemoradiation (CCR) for locally advanced or relapsed vulvar carcinoma (VC) treatment: An alternative to pelvic exenteration (PE)
Authors: H. Porcela, S. Gianni, A. M. Alvarez, D. De Dios, E. Mickiewicz, B. Roth, G. Cinat, P. Menendez, M. Bonomi
Journal: Journal of Clinical Oncology (2006)

15021 Background: PE is the standard treatment for locally advanced or relapsed VC that involves the anus or rectovaginal wall, with high morbidity and the consequent loss of Qol. Objective: Locoregional response, toxicity, disease free survival (DFS) and survival (SV) achieved with concurrent chemoradiation in locally advanced or relapsed VC was prospectively evaluated. Methods: From 7/93 to 05/05, 32 pts which would have required some kind of PE were treated with mitomycin C (10 mg./m 2 d1) + 5-Fluoruracil (800 mg/m 2 d 1–4) IV continuous infusion, plus concurrent external radiotherapy (50 Gy) to the vulva, pelvis and groin. An additional boost (15–20 Gy) was added when a less than complete clinical response (CR) was achieved. Multiple biopsies of the tumor bed were performed to confirm complete pathologic responses (CPR). Results: 30 pts (94%) completed treatment as planned. Overall, locoregional response was obtained in 25/30 (83.3%) pts: 20 (66.6%) CR, 5 (16.6%) partial response (PR). 3 (10%) pts had stable disease and 2 (6.6%) progresive disease. 14/30 (46.6%) had CPR. Radical vulvectomy or radical local excision was performed in 7 pts for residual disease after CCR (4/6 with CR and microscopic residual disease and 3/5 with PR), 2 pts with PR were lost after having completed CCR and 2 pts with CR and microscopic residual disease refused further treatment. None of the responding patients required PE. Treatment was well tolerated with mild to moderate toxicity, attributed to radiotherapy. No treatment deaths were recorded. 28 pts with a median follow-up of 25.5 months (range 6–126) showed a 5-year cumulative DFS (34%) and SV (49%). Conclusion: CCR is a safe therapeutic option with results comparable to those obtained with PE, with significant improvement of Qol. CCR has become the standard treatment for locally advanced or relapsed VC at our center. No significant financial relationships to disclose.
MITRAL VALVE CLIPPING FOR NEW ONSET DEGENERATIVE SEVERE MITRAL REGURGITATION IN A PATIENT WITH LEFT VENTRICULAR ASSIST DEVICE
Authors: Ayush Arora, Deepa Raghunathan, Wahaj Aman, Sriram Nathan, Marwan Jumean, Biswajit Kar
Journal: Journal of the American College of Cardiology (2020)
CLO20-059: Comparison of a Single Dose Immediate Instillation of Mitomycin C 20mg Versus 40mg in Prevention of Tumour Recurrence After Resection of Non Muscle Invasive Bladder Cancer
Authors: Shree Vishnu Siddarth, Ginil Kumar Pooleri, Georgie Mathew
Journal: Journal of the National Comprehensive Cancer Network (2020)

"CLO20-059: Comparison of a Single Dose Immediate Instillation of Mitomycin C 20mg Versus 40mg in Prevention of Tumour Recurrence After Resection of Non Muscle Invasive Bladder Cancer" published on 20 Mar 2020 by National Comprehensive Cancer Network.
The role of gamma-glutamyltransferase in malignant transformation and prognosis of ovarian cancer.
Authors: Richard Schwameis, Gerda Hofstetter, Stefanie Aust, Stephan Polterauer, Nicole Concin, Robert Zeillinger, Paul Speiser, Christian Marth, Alain G Zeimet, Alexander Reinthaller, Christoph Grimm
Journal: Journal of Clinical Oncology (2013)

e16524 Background: Gamma-glutamyltransferase (GGT) – a membrane bound enzyme crucially involved in the cell’s detoxification pathway and apoptotic balance – is involved in tumor development, progression and chemotherapy resistance. Elevated GGT serum levels are associated with increased cancer risk in women and worse prognosis in gynecologic cancers. The present study investigated the prognostic role of GGT in ovarian cancer patients. Methods: In this multi-center study, pre-therapeutic GGT levels were ascertained in 634 consecutive patients with epithelial ovarian cancer (EOC, n = 567) and borderline tumor of the ovary (BTO, n = 67). GGT serum levels were associated with clinico-pathological parameters and uni- and multivariate survival analyses were performed.Immunohistochemistry of GGT was performed in ovarian cancer tissue and correlated with GGT serum levels. Results: Pre-therapeutic GGT serum levels were higher in patients with EOC (28.56 [38.24] U/L) than in patients with BTO (20.01 [12.78] U/L, p = 0.01). High GGT serum levels were associated with advanced FIGO stage (p&lt;0.001) and with worse overall survival in univariate (p &lt; 0.001) and multivariable analysis (p=0.02, HR 1.2 [1.1-1.5]). We further investigated the association between systemic GGT serum levels and local GGT expression in EOC tumor tissue and observed an association between these two parameters (p = 0.03). Conclusions: High pre-therapeutic GGT serum levels are associated with advanced tumor stage and serve as an independent prognostic marker for worse overall survival in patients with EOC. GGT expression in ovarian cancer tissue is reflected in GGT serum levels.
Sputum and serum immunoglobulins in adult asthmatics with recurrent respiratory tract infections
Authors: Terence Ho, Eiman Al‐Selahi, Manali Mukherjee, Chynna Huang, Katherine Radford, Melanie Kjarsgaard, Nicola Lavigne, Janice Halabecki, Susan Waserman, Parameswaran Nair
Journal: Allergy (2020)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
The Evolutionary Origins of Recurrent Pancreatic Cancer
Authors: Hitomi Sakamoto, Marc A. Attiyeh, Jeffrey M. Gerold, Alvin P. Makohon-Moore, Akimasa Hayashi, Jungeui Hong, Rajya Kappagantula, Lance Zhang, Jerry P. Melchor, Johannes G. Reiter, Alexander Heyde, Craig M. Bielski, Alexander V. Penson, Mithat Gönen, Debyani Chakravarty, Eileen M. O'Reilly, Laura D. Wood, Ralph H. Hruban, Martin A. Nowak, Nicholas D. Socci, Barry S. Taylor, Christine A. Iacobuzio-Donahue
Journal: Cancer Discovery (2020)

Surgery is the only curative option for stage I/II pancreatic cancer; nonetheless, most patients will experience a recurrence after surgery and die of their disease. To identify novel opportunities for management of recurrent pancreatic cancer, we performed whole-exome or targeted sequencing of 10 resected primary cancers and matched intrapancreatic recurrences or distant metastases. We identified that recurrent disease after adjuvant or first-line platinum therapy corresponds to an increased mutational burden. Recurrent disease is enriched for genetic alterations predicted to activate MAPK/ERK and PI3K-AKT signaling and develops from a monophyletic or polyphyletic origin. Treatment-induced genetic bottlenecks lead to a modified genetic landscape and subclonal heterogeneity for driver gene alterations in part due to intermetastatic seeding. In 1 patient what was believed to be recurrent disease was an independent (second) primary tumor. These findings suggest routine post-treatment sampling may have value in the management of recurrent pancreatic cancer. SIGNIFICANCE: The biological features or clinical vulnerabilities of recurrent pancreatic cancer after pancreaticoduodenectomy are unknown. Using whole-exome sequencing we find that recurrent disease has a distinct genomic landscape, intermetastatic genetic heterogeneity, diverse clonal origins, and higher mutational burden than found for treatment-naïve disease.
Health profile of pediatric Special Immigrant Visa holders arriving from Iraq and Afghanistan to the United States, 2009–2017: A cross-sectional analysis
Authors: Simone S. Wien, Gayathri S. Kumar, Oleg O. Bilukha, Walid Slim, Heather M. Burke, Emily S. Jentes
Journal: PLoS Medicine (2020)

The United States has admitted over 80,000 Special Immigrant Visa holders (SIVH), which include children. Despite the increase in the proportion of SIVH admissions to the US over recent years, little is known about health conditions in SIV children. We report the frequency of selected diseases identified overseas and assess differences in selected conditions between SIV children from Iraq and Afghanistan.We analyzed 15,729 overseas medical exam data in Centers for Disease Control and Prevention's Electronic Disease Notification system (EDN) for children less than 18 years of age from Iraq (29.1%) and Afghanistan (70.9%) who were admitted to the US from April 2009 through December 2017 in a cross-sectional analysis. Variables included age, sex, native language, measured height and weight, and results of the overseas medical examination. From our analysis, less than 1% of SIV children (Iraqi: 0.1%; Afghan: 0.12%) were reported to have abnormal tuberculosis test findings, less than 1% (Iraqi: 0.3%; Afghan: 0.7%) had hearing abnormalities, and about 4% (Iraqi: 6.0% Afghan: 2.9%) had vision abnormalities, with a greater prevalence of vision abnormalities noted in Iraqis (OR: 1.9, 95% CI 1.6-2.2, p <0.001). Seizure disorders were noted in 46 (0.3%) children, with Iraqis more likely to have a seizure disorder (OR: 7.6, 95% CI 3.8-15.0, p < 0.001). On average, children from Afghanistan had a lower mean height-for-age z-score (Iraqi: -0.28; Afghan: -0.68). Only the data quality assessment for height for age for children ≥5 years fell within WHO recommendations. Limitations included the inability to obtain all SIVH records and self-reported medical history of noncommunicable diseases.In this investigation, we found that less than 1% of SIV children were reported to have abnormal tuberculosis test findings and 4% of SIV children had reported vision abnormalities. Domestic providers caring for SIVH should follow the US Centers for Disease Control and Prevention (CDC) Guidelines for the US Domestic Medical Examination for Newly Arriving Refugees, including an evaluation for malnutrition. Measurement techniques and anthropometric equipment used in panel site clinics should be assessed, and additional training in measurement techniques should be considered. Future analyses could further explore the health of SIV children after resettlement in the US.
Menstrual status and lung cancer in female patients from the Spanish WORLD07 database.
Authors: Blanca Cantos, Margarita Majem, Pilar Garrido López, Nuria Vinolas, Dolores Isla, M. Rosario Garcia-Campelo, Silvia Catot, Pilar Lianes, Angel Artal, Isabel Bover, Josefa Terrasa, Ana Blasco, Christian Diego Rolfo, Javier De Castro, Jose-Luis Gonzalez-Larriba, Martin Lazaro Quintela, Angel Izquierdo, Sergio Vazquez Estévez, Salvador Figueroa, Enriqueta Felip
Journal: Journal of Clinical Oncology (2012)

e12012 Background: There is very little information about the menstrual status in women presenting with lung cancer. In other tumors, the menstrual status constitutes an independent prognostic factor. We proposed to investigate whether this status has any influence in clinical aspects, diagnosis or survival. Methods: WORLD07 is a Spanish prospective, multicenter, epidemiologic female-specific lung cancer database sponsored by ICAPEM, a professional association committed to WLC research. Results: Between October/2007 and October/2011, 1371 p newly diagnosed WLC were included in an e-database from 32 Spanish centers. Patient (p) characteristics were: median age 71.1 years (y)(range 22-91); median age of menarche 13y.; motherhood 91.2% (median 2.3 children, median age at first child 26.4y); oral contraceptive use 11.9%; postmenopausal 86% (median age of menopause 49y. No statistically significant differences were found with respect to menstrual status, clinical characteristics, histological type, nor in the TNM at diagnosis. Median overall survival in pre-menopause (preM) was 24.2 months (m) and 27.5 m in post-menopause (postM). Overall 1 year survival in both groups was similar, 70% IC95% (61.5-79.1%) in preM vs 72.4% IC 95% (69.15-75.7%) in postM, and at 2 years, was 50% in both. Conclusions: According to our e-database, the menstrual status does not have any significant influence in the presentation, histologic type or survival in women with lung cancer.
Investigation of Presumptive HIV Transmission Associated with Hospitalization Using Nucleotide Sequence Analysis — New York, 2017
Authors: Bridget J. Anderson, Ernest Clement, Randall Collura, Abigail Gallucci, Emily Westheimer, Sarah Braunstein, Karen Southwick, Eleanor Adams, Emily Lutterloh, Charles Gonzalez, Robert McDonald, Hongwei Jia, William M. Switzer, Priti R. Patel, M. Patricia Joyce, Alexandra M. Oster
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

Health care associated transmission of human immunodeficiency virus (HIV) is rare in the United States; however, investigations of acute HIV infection in persons with recent health care exposure and no traditional risk factors should consider whether health care–associated transmission likely occurred.
EFFECT OF ALIROCUMAB ON FIRST AND TOTAL REVASCULARIZATIONS IN PATIENTS WITH RECENT ACUTE CORONARY SYNDROME IN THE ODYSSEY OUTCOMES TRIAL
Authors: Michael Szarek, Marco Valgimigli, Andreas Zeiher, Philippe Gabriel Steg, Deepak Bhatt, Vera Bittner, Chern-En Chiang, Rafael Diaz, Shaun Goodman, Nina Gotcheva, Robert A. Harrington, Johan Wouter Jukema, Hyo-Soo Kim, Yong-Un Kim, Joao Morais, Robert Pordy, Matthew Roe, Harvey White, Gregory G. Schwartz
Journal: Journal of the American College of Cardiology (2020)